Literature DB >> 2526127

Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin.

C de Vries1, H Veerman, H Pannekoek.   

Abstract

The binding of recombinant tissue-type plasminogen activator (rt-PA) to fibrin increases upon digestion of fibrin with plasmin. Optimal binding is observed following a limited plasmin digestion of fibrin, coinciding with the generation of fibrin fragment X polymers. We studied the involvement of the separate domains of the amino-terminal "heavy" (H) chain of rt-PA in this augmentation of fibrin binding. The fibrin-binding characteristics of a set of rt-PA deletion mutants, lacking either one or more of the structural domains of the H chain, were determined on intact fibrin matrices and on fibrin matrices that were subjected to limited digestion with plasmin. The augmented fibrin binding of rt-PA is partially abolished when the plasmin-degraded fibrin matrices are subsequently treated with carboxypeptidase B, demonstrating that this increased binding is dependent on the generation of carboxyl-terminal lysine residues in the fibrin matrix. Evidence is provided that this increase of fibrin binding is mediated by the kringle 2 (K2) domain that contains a lysine-binding site. Further increase of the fibrin binding of rt-PA is independent of the presence of carboxyl-terminal lysines. It is shown that the latter increase is not mediated by the K2 domain. Based on our data, we propose that the increase in fibrin binding, unrelated to the presence of carboxyl-terminal lysine residues, is mediated by the finger (F) domain, provided that this domain is correctly exposed in the remainder of the protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526127

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Binding and activation of human plasminogen by Mycobacterium tuberculosis.

Authors:  V Monroy; A Amador; B Ruiz; P Espinoza-Cueto; W Xolalpa; R Mancilla; C Espitia
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Inner clot diffusion and permeation during fibrinolysis.

Authors:  S L Diamond; S Anand
Journal:  Biophys J       Date:  1993-12       Impact factor: 4.033

3.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.

Authors:  Mariko Nagashima; Zheng-Feng Yin; Lei Zhao; Kathy White; Yanhong Zhu; Nina Lasky; Meredith Halks-Miller; George J Broze; William P Fay; John Morser
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

5.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

Authors:  J N Liu; V Gurewich
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

7.  Participation of the Dengue virus in the fibrinolytic process.

Authors:  V Monroy; B H Ruiz
Journal:  Virus Genes       Date:  2000-10       Impact factor: 2.198

8.  Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.

Authors:  Yogesh Kumar; Kanagasabai Vadivel; Amy E Schmidt; Godwin I Ogueli; Sathya M Ponnuraj; Nalaka Rannulu; Joseph A Loo; Madhu S Bajaj; S Paul Bajaj
Journal:  Biochemistry       Date:  2014-01-13       Impact factor: 3.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.